Asthma Clinical Trial
— DFUNBIOOfficial title:
Diaphragmatic Function as a Biomarker in Patients With Respiratory Diseases
NCT number | NCT05903001 |
Other study ID # | RWTHAachenU |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | July 1, 2023 |
Est. completion date | June 30, 2025 |
Dyspnea is among the most common symptoms in patients with respiratory diseases such as Asthma, chronic obstructive pulmonary disease (COPD), Fibrosis, and Pulmonary Hypertension. However, the pathophysiology and underlying mechanisms of dyspnea in patients with respiratory diseases are still poorly understood. Diaphragm dysfunction might be highly prevalent in patients with dyspnea and respiratory diseases. The association of diaphragm function and potential prognostic significance in patients with respiratory diseases has not yet been investigated.
Status | Recruiting |
Enrollment | 800 |
Est. completion date | June 30, 2025 |
Est. primary completion date | June 30, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - patient has one of the following lung diseases: COPD, bronchial asthma, pulmonary fibrosis, pulmonary hypertension - is 18 years or older - is mentally and physically able to understand the study and to follow instructions - are legally competent - signed declaration of consent Exclusion Criteria: - BMI > 35 - current or treatments or diseases in the past which could influence the evaluation of the study - Expected lack of willingness to actively participate in study-related measures - alcohol or drug abuse - disc herniation/prolapse - epilepsy - wheelchair bound - in custody due to an official or court order - in a dependent relationship or employment relationship with investigating physician or one of their deputy - emergency inpatient hospital stay within 4 weeks before study-specific examinations |
Country | Name | City | State |
---|---|---|---|
Germany | RWTH Aachen University Hospital | Aachen | North Rhine-westphalia |
Lead Sponsor | Collaborator |
---|---|
RWTH Aachen University |
Germany,
Balfanz P, Hartmann B, Muller-Wieland D, Kleines M, Hackl D, Kossack N, Kersten A, Cornelissen C, Muller T, Daher A, Stohr R, Bickenbach J, Marx G, Marx N, Dreher M. Early risk markers for severe clinical course and fatal outcome in German patients with COVID-19. PLoS One. 2021 Jan 29;16(1):e0246182. doi: 10.1371/journal.pone.0246182. eCollection 2021. — View Citation
Daher A, Balfanz P, Aetou M, Hartmann B, Muller-Wieland D, Muller T, Marx N, Dreher M, Cornelissen CG. Clinical course of COVID-19 patients needing supplemental oxygen outside the intensive care unit. Sci Rep. 2021 Jan 26;11(1):2256. doi: 10.1038/s41598-021-81444-9. — View Citation
Daher A, Balfanz P, Cornelissen C, Muller A, Bergs I, Marx N, Muller-Wieland D, Hartmann B, Dreher M, Muller T. Follow up of patients with severe coronavirus disease 2019 (COVID-19): Pulmonary and extrapulmonary disease sequelae. Respir Med. 2020 Nov-Dec;174:106197. doi: 10.1016/j.rmed.2020.106197. Epub 2020 Oct 20. — View Citation
Spiesshoefer J, Henke C, Herkenrath S, Brix T, Randerath W, Young P, Boentert M. Transdiapragmatic pressure and contractile properties of the diaphragm following magnetic stimulation. Respir Physiol Neurobiol. 2019 Aug;266:47-53. doi: 10.1016/j.resp.2019.04.011. Epub 2019 Apr 25. — View Citation
Spiesshoefer J, Henke C, Herkenrath S, Randerath W, Brix T, Young P, Boentert M. Assessment of Central Drive to the Diaphragm by Twitch Interpolation: Normal Values, Theoretical Considerations, and Future Directions. Respiration. 2019;98(4):283-293. doi: 10.1159/000500726. Epub 2019 Jul 26. — View Citation
Spiesshoefer J, Herkenrath S, Henke C, Langenbruch L, Schneppe M, Randerath W, Young P, Brix T, Boentert M. Evaluation of Respiratory Muscle Strength and Diaphragm Ultrasound: Normative Values, Theoretical Considerations, and Practical Recommendations. Respiration. 2020;99(5):369-381. doi: 10.1159/000506016. Epub 2020 May 12. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Dyspnea Borg scale 1 to 10 | Borg scale before and after "6 minute walking distance" test. Lower scores show fewer dyspnea, higher scores indicate more dyspnea. | 6 months recruiting | |
Primary | Dyspnea Borg scale 1 to 10 | Borg scale before and after "6 minute walking distance" test. Lower scores show fewer dyspnea, higher scores indicate more dyspnea. | follow up 3 months after recruitment | |
Primary | Dyspnea Borg scale 1 to 10 | Borg scale before and after "6 minute walking distance" test. Lower scores show fewer dyspnea, higher scores indicate more dyspnea. | follow up 6 months after recruitment | |
Primary | Dyspnea Borg scale 1 to 10 | Borg scale before and after "6 minute walking distance" test. Lower scores show fewer dyspnea, higher scores indicate more dyspnea. | follow up 12 months after recruitment | |
Primary | Dyspnea Borg scale 1 to 10 | Borg scale before and after "6 minute walking distance" test. Lower scores show fewer dyspnea, higher scores indicate more dyspnea. | follow up 18 months after recruitment | |
Secondary | 6 minute walking distance in m | Measurement of achieved walking distance in 6 minutes | 6 months recruiting | |
Secondary | Sit-to stand-test (60 seconds) | Measurement of achieved repetitions of standing up and sitting down from an initial seated position in 60 seconds. | 6 months recruiting | |
Secondary | New York Heart Association (NYHA) classification scale 1 to 4 | Patients are linked to a NYHA degree. Lower scores show fewer dyspnea, higher scores indicate more dyspnea. | 6 months recruiting, follow up up to 18 months after last recruitment | |
Secondary | Modified Medical Research Council (MRC) Breathlessness Scale 1 to 5 | Patients are assessed and grouped according to their MRC Breathlessness Scale. Lower scores show fewer dyspnea, higher scores indicate more dyspnea. | 6 months recruiting, follow up up to 18 months after last recruitment | |
Secondary | Chronic Respiratory Questionnaire (CRQ) | Assessments of different domains (Emotional Domain, Dyspnea Domain, Mastery Domain, Fatigue Domain) in a standardized questionnaire on a scale from 1 to 7. The scores for each question of each dimension are added together and divided by the number of completed questions in each domain. In general, higher scores mean a worse outcome and lower scores mean a better outcome.
For the dyspnea domain for example, a high score means that patients have less dyspnea, and a low score means that patients have more dyspnea. |
6 months recruiting, follow up up to 18 months after last recruitment | |
Secondary | COPD Assessment Test (CAT-Questionnaire) from 0 to 40 points. | Patients are evaluated and placed into the corresponding groups. Lower scores show fewer dyspnea, higher scores indicate more dyspnea. | 6 months recruiting, follow up up to 18 months after last recruitment | |
Secondary | Global Initiative for Asthma (GINA) classification | Patients are assessed and grouped as mild, moderate, or severe according to the GINA classification. | 6 months recruiting, follow up up to 18 months after last recruitment | |
Secondary | Body Plethysmography | TLC (Total lung capacity) in percent predicted. | 6 months recruiting | |
Secondary | Diaphragm Thickening Ratio (DTR) in percent | Via ultrasound, the diaphragm thickening ratio (DTR) was calculated as thickness at total lung capacity (TLC) divided by thickness at functional residual capacity (FRC). | 6 months recruiting | |
Secondary | Diaphragm thickness at Total lung capacity (TLC) | Via ultrasound, the diaphragm thickness at TLC is measured at the maximum point of inspiration. | 6 months recruiting | |
Secondary | Diaphragm thickness at functional capacity (FRC) | Via ultrasound, the diaphragm thickness at FRC is measured after a normal expiration. | 6 months recruiting | |
Secondary | Diaphragm ultrasound sniff velocity in cm/s | Via ultrasound, the diaphragm sniff velocity was assessed during tidal breathing and following a maximum sniff. | 6 months recruiting | |
Secondary | Intercostal Muscle ultrasound thickness at Total lung capacity (TLC) in cm | Via ultrasound, the intercostal thickness at TLC is measured at the maximum point of inspiration. | 6 months recruiting | |
Secondary | Intercostal Muscle ultrasound thickness at functional capacity (FRC) in cm | Via ultrasound, the intercostal thickness at FRC is measured after a normal expiration. | 6 months recruiting | |
Secondary | Intercostal Muscle Thickening Ratio in percent | Via ultrasound, the intercostal muscle thickening ratio was calculated as thickness at total lung capacity (TLC) divided by thickness at functional residual capacity (FRC). | 6 months recruiting | |
Secondary | Maximum Inspiratory Pressure (MIP) in percent predicted | Measurement of Maximum Inspiratory Pressure | 6 months recruiting | |
Secondary | Maximum Expiratory Pressure (MEP) in percent predicted | Measurement of Maximum Expiratory Pressure | 6 months recruiting | |
Secondary | Sniff Nasal Inspiratory Pressure (SNIP) in percent predicted | Measurement of Sniff Nasal Inspiratory Pressure | 6 months recruiting | |
Secondary | Blood Gas Analysis in cmH2O | oxygen partial pressure (pO2) | 6 months recruiting | |
Secondary | Blood Gas Analysis in cmH2O | carbon dioxide partial pressure (pCO2) | 6 months recruiting | |
Secondary | Blood Gas Analysis | pH scale | 6 months recruiting | |
Secondary | Blood Gas Analysis in mmol/l | Base Excess | 6 months recruiting | |
Secondary | Blood Gas Analysis in (I1/s) percent | Base Excess | 6 months recruiting | |
Secondary | Electromyography (EMG) | Measurement of electrical activity during different breathing maneuvers (Sniff, Cough, Valsalva, Mueller) via superficial electrodes placed on the diaphragm and accessory respiratory muscles (Sternocleidomastoideus muscle, intercostal muscles). | 6 months recruiting |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|